Evercore ISI Lowers Price Target for Viridian Therapeutics Ahead of Earnings
Evercore ISI has lowered its price target for Viridian Therapeutics (VRDN) from $32 to $24 ahead of its first-quarter earnings report, maintaining an 'Outperform' rating. The adjustment follows Amgen's positive Phase 3 results for Tepezza, which may increase competitive pressure on Viridian's thyroid eye disease therapy. VRDN's stock dropped 19% following the news.
Topics: analyst rating clinical trials competitive pressure earnings preview stock price movement